Clinical potential of C21 highlighted in review publications
Vicore Pharma (publ) (ticker VICO) has today published an updated reference list on the latest studies with the drug candidate C21. Three recent review articles, from Australia, Denmark/Florida and India respectively, summarize the pharmacological effects of C21 in specific indication areas. The conclusion of these reviews is that C21 has the potential to become a valuable addition to current medical treatment in several patient categories: as an anti-fibrotic agent for several indications, as a blood-pressure lowering agent in resistant hypertension, and as a nephroprotective medication for